Bayer has secured U.S. Food and Drug Administration (FDA) approval to market Lynkuet, its non-hormonal treatment for menopausal symptoms. The clearance provides the German pharmaceutical and life sciences group with a potential new revenue stream at a crucial juncture, as patent pressures mount on some of its older blockbuster drugs.
Financial Outlook and Legal Proceedings
The company’s leadership, under CEO Bill Anderson, reaffirmed its currency-adjusted revenue forecast for 2026, projecting it to land between 45 and 47 billion euros. This outlook comes despite a significant impact on free cash flow from special outflows, which are anticipated to be approximately 5 billion euros, largely tied to legal settlements.
On the legal front, developments are unfolding on two tracks. A Missouri court has granted preliminary approval to a proposed $7.25 billion settlement aimed at resolving a substantial portion of the remaining glyphosate-based litigation. A final confirmation hearing for this settlement is scheduled for July 2026.
Should investors sell immediately? Or is it worth buying Bayer?
Potentially more consequential in the near term is a hearing set for late April before the U.S. Supreme Court in the case of Monsanto v. Durnell. A favorable ruling for Bayer could fundamentally alter the legal landscape for damage claims in the United States, offering a prospective reduction to the group’s net liabilities, which recently stood at about 29.8 billion euros.
Launching a New Women’s Health Pillar
Lynkuet is designed to address vasomotor symptoms like hot flashes and night sweats without using hormones, offering an alternative for patients who cannot or prefer not to undergo classical hormone therapy. Bayer plans to support the product’s introduction with a major marketing campaign, aiming to capture market share early in this expanding therapeutic segment.
Bayer’s share price, while still trading roughly 23% below its 52-week high of €49.17, has shown a notable recovery from its low point in April of last year. The pace at which Lynkuet can build prescription volume in the U.S. market will be a key factor in determining whether the stock achieves a sustained re-rating or remains overshadowed by legal concerns. The upcoming Annual Stockholders’ Meeting on April 24 will provide the first public forum for discussion on this new chapter.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from March 29 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 29.
Bayer: Buy or sell? Read more here...
